Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors.

ABSTRACT:

Background

There are increasing concerns of cardiovascular safety related to endocrine therapy use in women with breast cancer (BC). We examined risk of cardiovascular disease (CVD) events and mortality associated with endocrine therapy use in postmenopausal women with early-stage BC.

Methods

Postmenopausal women diagnosed with stage I-III hormone receptor-positive BC from 2005 to 2013 were included (n = 8495). Women were classified as aromatase inhibitor (AI) users, tamoxifen users, and non-users of endocrine therapy in the 12 months after BC diagnosis. Likelihood ratio tests examined whether the association of endocrine therapy use with CVD and mortality outcomes varied by body mass index (BMI) and history of CVD before BC diagnosis.

Results

Over a median follow-up

SUBMITTER: Huang Y 

PROVIDER: S-EPMC12707390 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature